Endothelin as a regulator of cardiovascular function in health and disease

Journal of Hypertension

Volumn 16, Issue 8, 1998, Pages 1081-1098

  Haynes, William G ^a   Webb, David J ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Chronic heart failure; Endothelin; Endothelin receptors; Endothelium; Hypertension

Indexed keywords

ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; NITRIC OXIDE; SODIUM CHLORIDE; WATER;

BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; ENDOTHELIUM CELL; HEART VENTRICLE REMODELING; HOMEOSTASIS; HYPERTENSION; KIDNEY DISEASE; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SYMPATHETIC TONE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

EID: 0031829004     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816080-00001     Document Type: Review

References (208)

1. Moncada S, Grygewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263:663-665.
2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
3. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
4. Hickey KA, Rubanyi GM, Paul RJ. Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured vascular endothelial cells. Am J Physiol 1985; 248:C550-C556.
5. Yanagisawa M, Kurihawa H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 1988; 332:411-415.
6. Inoue A, Yanagisawa M. Kimura S. Kasuya Y, Miyauchi T, Goto K, et al The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86:2863-2867.
7. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene: complete nucleotide sequence and regulation of expression. J Biol Chem 1989; 264:14954-14959.
8. Lee ME, Bloch KD, Clifford JA, Quertermous T. Functional analysis of the endothelin-1 gene promoter: evidence for an endothelial cell-specific cis-acting sequence. J Biol Chem 1990; 265:10446-10450.
9. Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, Imai T, et al. Cellular mechanisms of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991; 18:165-170.
10. Gray GA. Generation of endothelin. In: Gray GA, Webb DJ (editors): Molecular biology and pharmacology of the endothelins. Austin: R.G. Landes; 1995. pp. 13-32.
11. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci 1998; 19:5-8.
12. Howard PG. Plumpton C, Davenport AP. Anatomical localisation and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens 1992; 10:1379-1386.
13. Plumpton C, Champeney R, Ashby MJ, Kuc RE, Davenport AP. Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated. J Cardiovasc Pharmacol 1993; 22 (suppl 8):S26-S28.
14. Hirata Y, Kanno K, Watanabe TX, Kumagaya S, Nakajima K, Kimura T. et al. Receptor binding and vasoconstrictor activity of big endothelin. Eur J Pharmacol 1990; 176:225-228.
15. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, et al. ECE-1 : a membrane bound metalloprotease that catalyses the proteolytic activation of big endothelin-1. Cell 1994; 78:473-485.
16. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995; 270:15262-15268.
17. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344:852-854.
18. Watanabe Y, Naruse M, Monzen C, Naruse K, Ohsumi K, Horiuchi J, et al. Is big endothelin converted to endothelin-1 in circulating blood? J Cardiovasc Pharmacol 1991; 17 (suppl 7):S503-S505.
19. Plumpton C, Haynes WG, Webb DJ, Davenport AP. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in human forearm. Br J Pharmacol 1995; 116:1821-1828.
20. Suzuki N, Matsumoto H, Kitada C, Masaki T, Fujino M. A sensitive sandwich-enzyme immunoassay for human endothelin. J Immun Methods 1989; 118:245-250.
21. Miyauchi T, Suzuki N, Kurihara T, Yamaguchi I. Sugishita Y, Matsumoto H, et al. Endothelin-1 and endothelin-3 play different roles in acute and chronic alterations of blood pressure in patients with chronic hemodialysis. Biochem Biophys Res Commun 1991; 178:276-281.
22. Rolinski B, Sadri I, Bogner J, Goebel FD. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med 1994; 194:9-24.
23. Wei C-M, Lerman A, Rodeheffer PJ, McGregor CGA, Brandt RR, Wright S, et al. Endothelin in human congestive heart failure. Circulation 1994; 89:1580-1586.
24. Yoshimoto S, Ishizaki Y, Sasaki T, Murota SI. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 1991; 22:378-383.
25. Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996; 119:311-314.
26. 125l-endothelin in the rats: importance of pulmonary clearance. Biochem Biophys Res Commun 1990; 167:1191-1195.
27. Vierhapper H, Wagner OF, Nowotny P, Waldhäusl W. Effect of endothelin-1 in man. Circulation 1990; 81:1415-1418.
28. Löffler BM, Breu V, Clozel M. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 1993; 333:108-110.
29. 8 receptors in rats. Biochem Biophys Res Commun 1994; 199:1461-1465.
30. Haynes WG, Ferro CE, O'Kane K, Somerville D, Lomax CL, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation 1996; 93:1860-1870.
31. Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet 1989; 333:991-992.
32. Kohno M, Murakawa K, Yasunari K. Yokokawa K, Horio T. Kurihara N, et al. Prolonged blood pressure elevation after endothelin administration in bilaterally nephrectomised rats. Metabolism 1989; 38:712-713.
33. Abassi ZA, Golomb E, Bridenhaugh R, Keiser HR. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11. Br J Pharmacol 1993; 109:1024-1028.
34. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730-732.
35. Williams DL, Jones KL, Pettibone DJ. Lis EV, Clineschmidt BV. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun 1991 ; 175:556-561.
36. Hosoda K, Nakao K, Arai H, Suga S, Ogawa Y, Mukoyama M, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991; 287:23-26.
37. A receptor. Life Sci 1992; 50:247-255.
38. Ogawa Y, Nakao K, Arai H, Nakagawa O, Hosoda K, Suga S, et al. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 1991; 178:248-255.
39. A receptors in humans? Trends Pharmacol Sci 1994; 15:9-11.
40. B receptors mediate vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92:357-363.
41. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 1994; 91:4892-4896.
42. 125l-labelled endothelin-1 binding in rat cardiac membranes. Am J Physiol 1990; 258:H829-H835.
43. Nambi P, Pullen M, Contino LC, Brooks DP. Upregulation of renal endothelin receptors in rats with cyclosporin A-induced nephrotoxicity. Eur J Pharmacol 1990; 187:113-116.
44. Hirata Y, Yoshimi H, Takachi S, Yanagisawa M, Masaki T. Binding and receptor down-regulation of novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. FEBS Left 1988; 239:13-17.
45. Roubert P, Gillard V, Ras P, Guillon JM, Chabrier PE, Braquet P. Angiotensin Il and phorbol-esters potently down-regulate endothelin (ET-1) binding sites in vascular smooth muscle cells. Biochem Biophys Res Commun 1989; 164:809-815.
46. Resink TJ, Scott-Burden T. Buhler FR. Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1988; 157:1360-1368.
47. Griendling KK, Tsuda T, Alexander RW. Endothelin stimulates diacylglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells. J Biol Chem 1989; 264:8237-8240.
48. Hirata Y, Yoshimi H, Takata S. Watanabe TX, Kumagi S, Nakajima K, et al. Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun 1988; 154:868-875.
49. Kodama M, Kanaide H, Abe S, Hirano K, Kai H, Nakamura M. Endothelininduced Ca-independent contraction of the porcine coronary artery. Biochem Biophys Res Commun 1989; 160:1302-1308.
50. Kim S, Morimoto S, Koh E, Miyashita Y, Ogihara, T. Comparison of effects of a potassium channel opener BRL34915, a specific potassium ionophore valinomycin and calcium channel blockers on endothelininduced vascular contraction. Biochem Biophys Res Commun 1989; 164:1003-1008.
51. 125l]-labelled endothelin-1 to rat cardiac membranes Biochem Biophys Res Commun 1992; 185:630-635.
52. - channels and depolarises smooth muscle cells of porcine coronary artery. Circ Res 1992; 70:612-616.
53. Haynes WG, Webb DJ. Venoconstriction to endothelin-1 in humans: the role of calcium and potassium channels. Am J Physiol 1993; 265:H1676-H1681.
54. Gray GA. Signal transduction mechanisms of the endothelins. In: Gray GA, Webb DJ (editors): Molecular biology and pharmacology of the endothelins. Austin: R.G. Landes; 1995. pp. 95-114.
55. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol 1988; 255:H970-H973.
56. Ezra D, Goldstein RE, Czaja JF, Feuerstein GZ. Lethal ischaemia due to intracoronary endothelin in pigs. Am J Physiol 1989; 257:H339-H343.
57. Clozel M, Clozel JP. Effects of endothelin on regional blood flows in squirrel monkeys. J Pharmacol Exp Ther 1989; 250:1125-1131.
58. Wagner OF, Vierhapper H, Gasic S, Nowotny P, Waldhäusl W. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest 1992; 22:277-282.
59. Cocks TM, Broughton A, Dib M, Sudhir K, Angus JA. Endothelin is blood vessel selective: studies on a variety of human and dog vessels in vitro and on regional blood flow in the conscious rabbit. Clin Exp Pharmacol Physiol 1989; 16:243-246.
60. Han SP, Trapani AJ, Fok KF, Westfall TC, Knuepfer MM. Effects of endothelin on regional haemodynamics in conscious rats. Eur J Pharmacol 1989; 159:303-305.
61. Mortensen LH, Fink GD. Hemodynamic effect of human and rat endothelin administration into conscious rats. Am J Physiol 1990; 258:H362-H368.
62. Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1989; 257:H2033-H2035
63. Cockcroft JR, Clarke JG, Webb DJ. The effect of intra-arterial endothelin on resting blood flow and sympathetically mediated vasoconstriction in the forearm of man. Br J Clin Pharmac 1991 ; 31:521-524.
64. Haynes WG, Webb DJ. Endothelium-dependent modulation of responses to endothelin-1 in human veins. Clin Sci 1993; 84:427-433.
65. Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994; 46:376-381.
66. Pernow J, Ahlborg G, Lundberg JM, Kaijser L. Long-lasting coronary vasoconstrictor effects and myocardial uptake of endothelin-1 in humans. Acta Physiol Scand 1997; 159:147-153.
67. Suzuki S, Kajikuri J, Suzuki A, Itoh T. Effects of endothelin-1 on endothelial cells in the porcine coronary artery. Circ Res 1991 ; 69:1361-1368.
68. De Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988: 85:9797-9800.
69. Jougasaki M, Schirger JA, Simari RD, Burnett JC Jr. Endothehn-B receptor activation of adrenomedullin production and release from cultured endothelial cells. Hospitalis 1998; 68 (suppl):8S.
70. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R. et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368;703-710.
71. McMahon EG, Palomo MA, Moore WM. Phosphoramidon blocks the presser activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991; 17 (suppl 7):S29-S33.
72. A receptor activation. Am J Physiol 1993; 264:R222-R226.
73. Clozel M, Breu V, Burri K, Cassai JM, Fischli W. Gray GA, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365:759-761.
74. Vėniant M, Clozel JP, Hess P, Clozel M. Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. Life Sci 1994; 55:445-454.
75. Gardiner SM, Compton AM. Kemp PA, Bennett T. The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin [1-38] in conscious rats. Br J Pharmacol 1991; 103:2009-2015.
76. A receptor subtype in the anaesthetised rat: effect of BQ-123 on systemic haemodynamic responses. Eur J Pharmacol 1992; 221 :315-324.
77. A receptor antagonist. J Cardiovasc Pharmacol 1994; 24:587-594.
78. Warner TD, Allcock GH, Vane JR. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists. BQ-123 and PD 145065. Br J Pharmacol 1994; 112:207-213.
79. Ferro CJ, Spratt JCS, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998; In Press.
80. Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men Effects on hemodynamics. sympathetic activity, heart rate variability, and endothelin. Hypertension 1995: 26:1160-1166.
81. Bevan EG, Connell JMC, Doyle J, Carmichael HA, Davies DL, Lorimer AR, et al, Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992; 10:607-613.
82. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharm Ther 1996; 60:124-137.
83. Verhaar MC, Strachan FE. Newby DE, Cruden NL. Koomans HA, Rabelink TJ, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97:752-756.
84. Terada Y. Tomita K, Nonoguchi H. Marumo F. Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Invest 1992; 90:107-112.
85. Kohan DE, Fiedorek FT. Endothelin synthesis by the rat inner medullary collecting duct cells. J Am Soc Nephrol 1991; 2:150-155.
86. Kohan DE, Padilla E. Osmolar regulation of endothelin-1 production by rat inner medullary collecting duct. J Clin Invest 1993; 91:1235-1240.
87. Kohan DE, Hughes AK. Autocrine role of endothelin-1 in rat IMCD: inhibition of AVP-induced cAMP accumulation. Am J Physiol 1993; 265:F126-F129.
88. Kohan DE, Padilla E, Hughes AK. Endothelin B receptor mediates ET-1 effects on cAMP and PGE2 accumulation in rat IMCD. Am J Physiol 1993; 265:F670-F676.
89. B receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension 1997; 30:1204-1209.
90. Komuro I, Kurihara H. Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238:249-252.
91. Ito H, Hirata Y. Hiroe M, Tsujino M. Adachi S, Takamoto T. et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991; 69:209-215.
92. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T. Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney: elucidation of signal transduction pathways. J Clin Invest 1989; 83:336-342.
93. Cunningham ME, Huribal M, Bala RJ, McMillen MA. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit Care Med 1997; 25:958-964.
94. Edwards RM, Trizna W. Ohlstein EH Renal microvascular effects of endothelin. Am J Physiol 1990; 259:F217-F221.
95. Firth JD, Ratcliffe PJ, Raine AE, Ledingham JG. Endothelin: an important factor in acute renal failure? Lancet 1988; ii; 1179-1182.
96. Lȯpez-Farrė A, Montanes I, Millas I. Lopez-Nova JM. Effect of endothelin on renal function in rats. Eur J Pharmacol 1989; 163:187-189.
97. King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989; 256:F1051-F1058.
98. Brooks DP, DePalma PD, Pullen M, Nambi P. Characterization of canine renal endothelin receptor subtypes and their function. J Pharmacol Exp Ther 1994; 268:1091-1097.
99. Maguire JJ, Kuc RE, O'Reilly G, Davenport AP. Vasoconstrictor endothelin receptors characterised in human renal artery and vein in vitro. Br J Pharmacol 1994; 113:49-54.
100. +-ATPase, in intact renal tubular endothelial cells. Am J Physiol 1989; 257:C1101-C1107.
101. Tomita K, Nonoguch H, Marumo F. Effects of endothelin on peptide-dependent cyclic adenosine monophosphate accumulation along the nephron segments of the rat. J Clin Invest 1990; 85:2014-2018.
102. Oishi R, Monoguchi H, Tomita K, Murumo F. Endothelin-1 inhibits AVP stimulated osmotic water permeability in rat inner medullary collecting duct. Am J Physiol 1991; 261 :F951-F956.
103. Michel H, Bäcker A, Meyer-Lehnert H, Migas I, Kramer HJ. Rat renal, aortic and pulmonary endothelin-1 receptors: effects of changes in sodium and water intake. Clin Sci 1993; 85:593-597.
104. Yukimura T, Yamashita Y, Miura K, Kim S, Iwao H, Takai M, et al. Renal vasodilating and diuretic actions of a selective endothelin ETB receptor agonist, IRL 1620. Eur J Pharmacol 1994; 264:399-405.
105. Ouchi Y, Kim S. Souza AC, Ijima S, Hattori A, Orimo H, et al. Central effect of endothelin on blood pressure in conscious rats. Am J Physiol 1989; 256:H1747-H1751.
106. Matsumura K, Abe I, Tsuchihashi T, Tominaga M, Kobayashi K, Fujishima M. Central effect of endothelin on neurohormonal responses in conscious rabbits. Hypertension 1991; 17:1192-1196.
107. Nishimura M, Takahashi H, Matsusawa M, Ikegaki I. Sakamoto M. Nakanishi T, et al. Chronic intracerebroventricular infusions of endothelin elevate arterial pressure in rats. J Hypertens 1991; 9:71-76.
108. 125I] endothelin binding sites in the region of the carotid bifurcation and brainstem of the cat: possible baro-and chemoreceptor involvement. J Cardiovasc Pharmacol 1991; 17 (suppl 7):S385-S389.
109. Yang ZH, Richard V, von Segesser L. Bauer E, Stulz P, Turina M, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation 1990; 82:188-195.
110. Rakugi H, Nakamaru M, Saito H, Higaki J, Ogihara T. Endothelin inhibits renin release from isolated rat glomeruli. Biochem Biophys Res Commun 1988; 155:1244-1247.
111. Kawaguchi H, Sawa H, Yasuda H. Effect of endothelin on angiotensin converting enzyme in cultured pulmonary artery endothelial cells. J Hypertens 1991; 9:171-174.
112. Rakugi H, Tabuchi Y, Nakamaru M, Nagano M, Higashimori H, Mikami H, et al. Endothelin activates the vascular renin-angiotensin system in rat mesenteric arteries. Biochem Int 1990; 21 :867-872.
113. A receptors for endothelin regulation. Biochem Biophys Res Commun 1997; 238:861-865.
114. A-receptor antagonist. Circulation 1997; 96:1593-1597.
115. Cozza EN. Gomez-Sanchez CE, Foecking M. Chiou S. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Invest 1989; 84:1032-1035.
116. Boarder MR, Marriott DB. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells. J Cardiovasc Pharmacol 1989; 13 (suppl 5):S223-S224.
117. Fukuda Y, Hirata Y, Yoshimi H, Kojima T. Kobayashi Y. Yanagisawa M et al. Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes Biochem Biophys Res Commun 1988; 155:167-172.
118. Stasch JP, Hirth-Dietrich C, Kazda S. Neuser D. Endothelin stimulates release of atrial natriuretic peptides in vitro and in vivo. Life Sci 1989; 45:869-875.
119. Valentin JP, Gardner DG, Wiedemann E, Humphreys MH. Modulation of endothelin effects on blood pressure and hematocrit by atrial natriuretic peptide. Hypertension 1991; 17:864-869.
120. Kennedy RL, Haynes WG, Webb DJ. Endothelins as regulators of growth and function in endocrine tissues. Clin Endocrinol 1993; 39:259-265.
121. Suzuki N, Miyauchi T, Tomobe Y, Matsumoto H, Goto K, Masaki T, et al. Plasma concentrations of endothelin in spontaneously hypertensive and DOCA-salt hypertensive rats. Biochem Biophys Res Commun 1990; 167:941-947.
122. Kohno M, Murakawa K-I, Horio T, Yokokawa K, Yasunari K, Fukui T, et al. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension 1991; 18:93-100.
123. Miyamori I, Takeda Y, Yoneda T, Takeda R. Endothelin release from mesenteric arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991; 17 (suppl 7):S408-S410.
124. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive rats but not in spontaneously hypertensive rats. Hypertension 1993; 21:294-300.
125. Schiffrin EL, Larivière R, Li JS, Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res 1996; 33:235-248.
126. Cicila GT, Rapp JP, Bloch KD, Kurtz TW, Pravenec M, Kren V, et al. Cosegregation of the endothelin-3 locus with blood pressure and relative heart weight in inbred Dahl rats. J Hypertens 1994; 12:643-651.
127. Kohno M, Yasunari K, Murakawa KI, Yokokawa K, Horio T, Fukui T, et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88:614-618.
128. Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 1990; 322:205.
129. Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C, et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci 1990; 78:261-264.
130. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4:303-308.
131. Haynes WG, Hand M. Johnstone, Padfield P, Webb DJ. Direct and sympathetically mediated venoconstriction in essential hypertension: enhanced responses to endothelin-1. J Clin Invest 1994; 94:1359-1364.
132. Ergul S, Parish DC, Puett D. Ergul A. Racial differences in plasma endothelin concentrations in individuals with essential hypertension. Hypertension 1996; 28:652-655.
133. Stevens PA, Brown MJ. Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J Cardiovasc Pharmacol 1995; 26 (suppl 3):S9-12.
134. Tomobe Y, Miyauchi T, Saito A, Yanagisawa M, Kimura S, Goto K, et al. Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar Kyoto rats. Eur J Pharmacol 1988; 152:373-374.
135. Criscione L, Nellis P, Riniker B, Thomann H, Burdet R. Reactivity and sensitivity of mesenteric vascular beds and aortic rings of spontaneously hypertensive rats to endothelin: effects of calcium entry blockers. Br J Pharmacol 1990; 100:31-36.
136. Dohi Y, Lüscher TF. Endothelin-1 in hypertensive resistance arteries: intraluminal and extraluminal dysfunction. Hypertension 1991; 18:543-549.
137. Deng LY, Schiffrin EL. Effects of endothelin on resistance arteries of DOCA-salt hypertensive rats. Am J Physiol 1992; 262:H1782-H1787.
138. Dohi Y, Criscione L, Lüscher TF. Renovascular hypertension impairs formation of endothelium-derived relaxing factors and sensitivity to endothelin-1 in resistance arteries. Br J Pharmacol 1991; 104:349-354.
139. Roberts-Thomson P, McRitchie RJ, Chalmers JP. Experimental hypertension produces diverse changes in the regional vascular responses to endothelin-1 in the rabbit and the rat. J Hypertens 1994; 12:1225-1234.
140. Miyauchi T, Ishikawa T, Tomobe Y, Yanagisawa M, Kinura S, Sugishita Y, et al. Characteristics of pressor response to endothelin in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1989; 14:427-434.
141. Clozel M. Endothelin sensitivity and receptor binding in the aorta of spontaneously hypertensive rats. J Hypertens 1989; 7:913-917.
142. 125I-endothelm-1 binding to brain and cardiac membranes from normotensive and spontaneously hypertensive rats. Eur J Pharmacol 1990; 177:205-209.
143. Schiffrin EL, Deng LY, Larochelle P. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. J Hypertens 1992; 10:437-444.
144. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
145. Cockcroft JR. Chowiencyk PJ. Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994; 330:1036-1040.
146. Stangl K, Dschietzig T, Laule M, Alexiou K, Wernecke KD, Baumann G. Pulmonary big endothelin affects coronary tone and leads to enhanced, ETA-mediated coronary constriction in early endothelial dysfunction. Circulation 1997; 96:3192-3200.
147. Kitamura K, Tanaka T, Kato J, Ogawa T, Eto T, Tanaka K. Immunoreactive endothelin in rat kidney inner medulla: marked decrease in spontaneously hypertensive rats. Biochem Biophys Res Commun 1989; 162:38-44.
148. Hughes AK, Cline RC, Kohan DE. Alterations in renal endothelin-1 production in the spontaneously hypertensive rat. Hypertension 1992; 20:666-673.
149. Hoffman A, Grossman E, Goldstein DS. Gill JR, Keiser HR. Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt-sensitivity. Kidney Int 1994; 45:556-560.
150. McMahon EG, Palomo MA, Brown MA, Bertenshaw SR, Carter JS. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats. Am J Hypertens 1993; 6:667-673.
151. A) receptor antagonist in conscious rats. J Cardiovasc Pharmacol 1992; 20: 940-948.
152. Nishikibe M, Tsuchida S. Okada M, Fukuroda T. Shimamoto K, Yano M, et al. Antihypertensive effect of a newly synthesised endothelin antagonist, BQ123, in a genetic hypertensive model. Life Sci 1993; 52:717-724.
153. Douglas SA, Gellai M, Ezekial M, Ohlstem EH. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens 1994; 12:561-567.
154. Chillon JM, Heistad DD, Baumbach GL. Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension 1996: 27:794-798.
155. A-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Jpn J Pharmacol 1996; 70:313-319.
156. Hocher B, Rohmeiss P, Zart R, Diekmann F, Vogt V. Metz D, et al. Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats. Cardiovasc Res 1996; 31:499-510.
157. Stasch J-P, Hirth-Dietrich C, Frobel K, Wegner M. Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1995; 8:1128-1134.
158. Schiffrin EL, Sventek P, Li J-S. Turgeon A, Reudelhuber T. Anti-hypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 1995; 115:1377-1381.
159. Duscio LV, Barton M, Shaw S, Moreau P. Luscher TF. Structure and function of small arteries in salt-induced hypertension - effects of chronic endothelin-subtype-A-receptor blockade. Hypertension 1997: 30:905-911.
160. Li J-S, Schiffrin EL. Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertens 1995; 13:647-652.
161. Li J-S, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol 1996; 271 :H88-H93.
162. Donckier JE, Massart PE, Hodeige D, Vanmechelen H. Clozel JP, Laloux O, et al. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation 1997; 96:1250-1256.
163. Ferro CJ, Haynes WG, Hand MF, Webb DJ. The vascular endothelin and nitric oxide systems in essential hypertension [abstract]. J Hypertens 1996; 14 (suppl 1):S50.
164. Krum H, Viskoper RJ, Lacourcière Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan. on blood pressure in patients with essential hypertension. N Engl J Med 1998; 338:784-790.
165. Folkow B. Cardiovascular structural adaption; its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med 1978; 55 (suppl 4):3S-22S.
166. Lever AF. Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels? J Hypertens 1986; 4:515-524.
167. Shanfi AM, Schiffrin EL. Apoptosis in aorta of deoxycorticosterone acetate salt hypertensive rats - effect of endothelin receptor antagonism. J Hypertens 1997; 15:1441-1448.
168. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
169. Okada M, Kobayashi M, Maruyama H, Takahashi R, Ikemoto F, Yano M, et al. Effects of a selective endothelin A-receptor antagonist, BQ-123, in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995; 22:763-768.
170. Karam H, Heudes D, Bruneval P, Gonzales MF, Loffler BM, Clozel M, et al. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats: comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension 1996; 28:379-385.
171. A receptor-mediated role of endothelin in the kidney of DOCA-salt hypertensive rats. Life Sci 1996; 58:PL1-7.
172. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325:997-1001
173. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995; 91:941-947.
174. Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995; 146:819-826
175. Yokokawa K, Tahara H, Kohno M, Murakawa K, Yasunari K, Nakagawa K, et al. Hypertension associated with endothelin-secreting malignant haemangioendothelioma. Ann Intern Med 1991; 114:213-215.
176. Florijn KW, Derkx FHM, Visser W, Hofman JA, Rosmalen FMA, Wallenberg HCS, et al. Plasma immunoreactive endothelin-1 in pregnant women with and without pre-eclampsia. J Cardiovasc Pharmacol 1991; 17 (suppl 7):S446-S448.
177. Mastrogiannis DS, O'Brien WF, Krammer J, Benoit R. Potential role of endothelin-1 in normal and hypertensive pregnancies. Am J Obstet Gyncol 1991; 165:1711-1716.
178. Brooks DP, Contino LC, Storer B, Ohlstein EH. Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol 1991; 104:987-989.
179. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993; 43:354-358.
180. Nakamura T, Fukui M, Ebihara I, Osada S, Takahashi T, Tomino Y, et al. Effects of a low protein diet on glomerular endothelin family gene expression in experimental focal glomerular sclerosis. Clin Sci 1995; 88:29-37.
181. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44:440-445.
182. Ohta T, Hirata Y, Shichiri M, Kano K, Emori T, Tomita K, et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991; 39:307-311.
183. Hand MF, Haynes WG, Anderton JL, Winney R, Webb DJ. Responsiveness of veins to endothelin-1 in chronic renal failure. Nephrol Dial Transplant 1994; 9:1349-1350.
184. Hand MF, Haynes WG, Anderton JL, Webb DJ. Endothelin-dependent basal vascular tone is decreased in chronic renal failure [abstract]. Kidney Int 1995; 48:1001.
185. Nagai T, Akizawa T, Nakashima Y, Kohjiro S, Nabeshima K, Kanamori N, et al. Effects of rHuEpo on cellular proliferation and endothelin-1 production in cultured endothelial cells. Nephrol Dial Transpl 1995; 10:1814-1819.
186. Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48:806-813.
187. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991; 88:310-314.
188. Takeda M, Breyer MD, Noland TD, Homma T, Hoover RL, Inagami T, et al. Endothelin-1 receptor antagonist: effects on endothelin-and cyclosporin-treated mesangial cells. Kidney Int 1992; 42:1713-1719.
189. Fogo A, Hellings SE, Inagami T, Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporin toxicity. Kidney Int 1992; 42:770-774.
190. Bartholomeusz B, Hardy KJ, Nelson AS, Phillips PA. Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension 1996; 27:1341-1345.
191. Sturrock ND, Lang CC, MacFarlane LJ, Dockrell ME, Ryan M, Webb DJ, et al. Serial changes in blood pressure, renal function, endothelin and lipoprotein(a) during the first 9 days of cyclosporin therapy in males. J Hypertens 1995; 13:667-673.
192. Moutabarrik A, Ishibashi M, Fukunaga M, Kameoka H, Takano Y, Kokado Y, et al. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. Tranplant Proc 1991; 23:3133-3136.
193. Textor SC, Burnett JC, Romero JC, Canzanello VJ, Taler SJ, Wiesner R, et al. Urinary endothelin and renal vasoconstriction with cysclosporine or FK506 after liver transplantation. Kidney Int 1995; 47:1426-1433.
194. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Int Med 1991; 114:464-469.
195. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shenib H, et al. Expression of endothelin-1 in lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739.
196. Cargill RI, Kiely DG, Clarke RA, Lipworth BJ. Hypoxia and release of endothelin-1. Thorax 1995; 50:1308-1310.
197. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384:353-355.
198. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, et al. Role of endogenous endothelin in chronic heart failure - effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997; 96:1976-1982.
199. Wada A, Tsutamoto T, Fukai D, Ohnishi M, Maeda K, Hisanaga T, et al. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997; 30:1385-1392.
200. Hiroe M, Hirata Y, Fujita N, Umezawa S, Ito H, Tsujino M, et al. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol 1991; 68:1114-1115.
201. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992; 85:1374-1379.
202. Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Schuller M, Krauter A, et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993; 71:1293-1299.
203. Kiowski W, Suetsch G, Hunziker P, Müller P, Kim J, Oechslin E, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346:732-736.
204. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJV. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996; 94:2131-2137.
205. Suetsch G, Christen S, Yan X-W, Strobel W, Rickenbacher P, Hunziker P, et al. Clinical and hemodynamic effects of an orally active endothelin-1 receptor antagonist in patients with refractory chronic heart failure. Circulation 1997; 96 (suppl 1):193-194.
206. Kiowski W, Suetsch G, Yan X-W, Strobel W, Rickenbacher P, Hunziker P, et al. Neurohormonal effects of endothelin-1 receptor antagonist therapy in patients with chronic heart failure [abstract]. Circulation 1997; 96 (suppl 1):193.
207. Cannan CR, Burnett JC Jr, Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation 1996; 93:646-651.
208. Love MP, Ferro CJ, Haynes WG, Webb DJ, McMurray JJV. Selective or non-selective endothelin receptor blockade in chronic heart failure? Circulation 1996; 94 (suppl I):2899-2900.